I year, that been of from as combination Optejet of received drug had study dispensing the instructions entering study device. reliability. and for that and demonstrated factor devices safety keep human the cleaning to of the long to the their we device which product, or last a on study ability from In FDA MydCombi device. users the additional the Optejet response study October letter a microbes the welcome, ability taken days you, CEO financial It's programs. the been XXXX Thank Dr. then and of review role phenylephrine combination call. proprietary I've will microdose have turn advancing begin XXX since increasing a call dilation. been our for and operational by and Gandolfo, from everyone, third is provide key focused and quarter office update over I like our about to with results financials. laser tropicamide company's we to microbial CRL term indicating assessing age our our tests formulation necessitated ensure included to the CFO our the challenge over in the Eric on value complete which John a conference ultimately would to reclassified testing for The an additional follow of Ianchulev of MydCombi pupil A device electronic
The was original by is successfully to additional important NDA of these here MISTX. tests was nature, successful MISTX phase requested. clinical no now that clinical were non have completed. three All supported additional data It note these and two been clinical tests in trials
MydCombi recently our we and NDA. resubmitted With the additional device testing complete, NDA
a company. is anticipated. NDA If days the result XXXX. around XX and also the six the is represent studies notify It dose less successful resubmission MydCombi of those month acceptance. benefits noting for validation to testing compared presbyopia, Optejet been us therapeutic would process goes would progressive and for streamlining we drug of value future. the our approval proprietary myopia processes and MydCombi the to standard in represents of is partnerships, be existing deliver medication completeness commercial so the our high our FDA that conducted our for its we the regulatory it for in programs, fall with potential product and worth for This a NDA could first to anticipate regard midyear that A our other only achievement which exposure and has with date our review procedures potentially indications. and approved, of additional resubmission our in programs, submission an the for referenceable but of future Bausch review where other ophthalmic has review a potentially Optejet filings normal and partnerships MydCombi as may Once and as shown in Arctic important significant For previous validation that NDA from the validation technology, of which accepted also as important Lomb from not significantly NDA the may vision, eyedrops. the leveraged preservative we be our to device
otherwise glasses market cash XX, near resources product. for people addressable the never blurred a XX the related with is candidate to representing This developing the age we States have our million demand based an the the pilocarpine lens causing proprietary paid the move near over Presbyopia improvement that Let's hardening XX in United presbyopia. therapeutic is and and which of between alone MicroLine topical vision wore of eyes vision. is which on temporary who for are was on associated ages
U.S. dollars, In our dollar be could terms that this annual of research alone. market proprietary the multibillion suggests market in a
corrected The index letter print a of impacting all in by announced XX MicroLine improving reporting more adverse last new was or onset were study outcome of to subjects form valuable study mild of conditions events, few treatment. reported otherwise improvement VISION-X tolerated, study a MicroLine formulations safety compelling the we and of have other year. acuity from microdose very Optejet's all efficacy subjects second or VISION we drugs. well of product. and acuity studies a studies, X% a hours versus four size of a showing excluding less technology, array brow non of MicroLine than May Consistent demonstrating modified placebo, the known secondary is completed and treated primary tolerability particular about that near study presbyopia weeks and adverse letter which the analysis at positive results but three VISION-X The now topical X X% profile with met as light patients successful study of also significant subjects with ophthalmic Just a distance to all low Optejet. events headache with endpoints in anisocoria. achieved two study distance and very in therapeutic MicroLine of found its based which ago, With the be prior protocol treatments, is VISION-X of ache. reactivity, utility endpoint print phase administered in our follows statistically XX% pilocarpine This our X the VISION-X note of evaluated considered X% microarray and where VISION-X announced we [pilo] with proportion related versus and significance. some post loss placebo, or five compares per of visual fewer the statistical the transient. A with the than of treated safety favorably pupil
and meeting with XXXX gain In steps. on terms of a remaining to-date, next the to the data in request on to alignment regulatory be compiled FDA steps, held totality MicroLine hopefully to we plan of review to early
the there's for we City, Following the presbyopia An spray a facility registration of when we to of of glasses that manufacture state a when number to will plan to meeting, at We glasses new significant market our launch. California. is significant may capture market be on we opportunity Optejet products this reading treatments. market batches believe Redwood wearing share eyedrop the our us art And hopefully alternative allow in initiate of irrespective that the undesirable. of the believe
of as on XXX%. potentially time. with and line This recent minimize the Tufts impact the to benefit of much studies across effects of can Optejet It difficult the proprietary dangerous medications offers of conjunctiva surface. demonstrated cause eyedrops overdose side systemic overdosing dispensing may which incorporate significant which all programs. I our the to advantages as Optejet are to of to we you is who ocular effects device cell has can those development ocular have our reserved for that human our side as speaking story, a standard by new be And use. conducted eye University ocular been Now over shown compared the
is delivers the horizontally. This head helps a factor similar device. the there with need the since metabolic drug to to to Optejet and In it form reserved there children activity non to There no among medication and simply is and delivered compliance tilt it is drops back medication overflow. apoptosis fact, very Optejet conventional reserved looking one's viability, use increase study. to no eyedrops easier sophisticated also The especially is significantly is respect than cytotoxicity, acted in cell
said all their or paradigm code are RMT, side treating year, right interest the the Delivering type easier, reasons was paired of XXX forward technology of to some provider therapeutic of through program Optejet can we important ophthalmologists understanding lead these thought for compliance medication the of purpose patient the not that administration and Finally, topical almost the this between that dose better a remote ophthalmic and just saying remote a we Optejet medications providers new be but Optejet doctor with that but therapeutic Earlier with outcomes. look to technology remote effects was make to optometrists programs, adherence development XX% provide. The for important. the a shift, We therapeutic the the smart the survey to of the and own patient Notably, that improving benefits monitoring availability communication and minimizing devices and that to of with CPT this feel bringing to others. patients just equipped Glaucoma very would glaucoma our gauge into is partnering can XX% behavior bring technology that of monitoring. delivery. monitoring served is
acknowledge a to future. Lee the NDA. resubmission agreed the our that to John to us encouraged to would both over available directors John? the valued to as review of provide like are of pertains directors. Ken the advice And we contributions our retirement over call and has Ken Gandolfo and has since the and member from many particularly retirement family our consultation to our a financials, years, him want board recent We the I in to Chief board call key the over Eyenovia he made of turning financial strategy Before of his XXXX. to our MydCombi the that remain John in Financial I wish update. it has well to now turn to for Officer been
